Nick Li is currently senior director and head of health economics and outcomes research at uniQure, a leading gene therapy company. Nick is a value and access leader in building global HEOR functions, integrating HEOR into development and commercialization process, optimizing product value proposition throughout life cycle, and delivering reimbursement successes for innovative products. Nick has a solid track record of making impacts on business. Prior to uniQure, he led HEOR efforts at Bioverativ for rare blood disorder franchise, including global launch of the first extended half-life hemophilia products Eloctate and Alprolix. He has also worked on other major brands in multiple therapeutic areas, including hematology/oncology, rheumatology, cardiovascular, and metabolic diseases.